2bnr: Difference between revisions
New page: left|200px<br /> <applet load="2bnr" size="450" color="white" frame="true" align="right" spinBox="true" caption="2bnr, resolution 1.9Å" /> '''STRUCTURAL AND KINET... |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:2bnr.gif|left|200px]]<br /> | [[Image:2bnr.gif|left|200px]]<br /><applet load="2bnr" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="2bnr" size=" | |||
caption="2bnr, resolution 1.9Å" /> | caption="2bnr, resolution 1.9Å" /> | ||
'''STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES'''<br /> | '''STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES'''<br /> | ||
==Overview== | ==Overview== | ||
Analogue peptides with enhanced binding affinity to major | Analogue peptides with enhanced binding affinity to major histocompatibility class (MHC) I molecules are currently being used in cancer patients to elicit stronger T cell responses. However, it remains unclear as to how alterations of anchor residues may affect T cell receptor (TCR) recognition. We correlate functional, thermodynamic, and structural parameters of TCR-peptide-MHC binding and demonstrate the effect of anchor residue modifications of the human histocompatibility leukocyte antigens (HLA)-A2 tumor epitope NY-ESO-1(157-165)-SLLMWITQC on TCR recognition. The crystal structure of the wild-type peptide complexed with a specific TCR shows that TCR binding centers on two prominent, sequential, peptide sidechains, methionine-tryptophan. Cysteine-to-valine substitution at peptide position 9, while optimizing peptide binding to the MHC, repositions the peptide main chain and generates subtly enhanced interactions between the analogue peptide and the TCR. Binding analyses confirm tighter binding of the analogue peptide to HLA-A2 and improved soluble TCR binding. Recognition of analogue peptide stimulates faster polarization of lytic granules to the immunological synapse, reduces dependence on CD8 binding, and induces greater numbers of cross-reactive cytotoxic T lymphocyte to SLLMWITQC. These results provide important insights into heightened immunogenicity of analogue peptides and highlight the importance of incorporating structural data into the process of rational optimization of superagonist peptides for clinical trials. | ||
==Disease== | ==Disease== | ||
Line 11: | Line 10: | ||
==About this Structure== | ==About this Structure== | ||
2BNR is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http:// | 2BNR is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2BNR OCA]. | ||
==Reference== | ==Reference== | ||
Line 18: | Line 17: | ||
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
[[Category: Bossi, G.]] | [[Category: Bossi, G.]] | ||
[[Category: Boultier, J | [[Category: Boultier, J M.]] | ||
[[Category: Cerundolo, V.]] | [[Category: Cerundolo, V.]] | ||
[[Category: Chen, J | [[Category: Chen, J L.]] | ||
[[Category: Choi, E | [[Category: Choi, E M.L.]] | ||
[[Category: Dunbar, P | [[Category: Dunbar, P R.]] | ||
[[Category: Esnouf, R | [[Category: Esnouf, R M.]] | ||
[[Category: Griffiths, G.]] | [[Category: Griffiths, G.]] | ||
[[Category: Held, G.]] | [[Category: Held, G.]] | ||
[[Category: Jackobsen, B | [[Category: Jackobsen, B K.]] | ||
[[Category: Jones, E | [[Category: Jones, E Y.]] | ||
[[Category: Lissin, N | [[Category: Lissin, N M.]] | ||
[[Category: Merwe, P | [[Category: Merwe, P A.Van Der.]] | ||
[[Category: Renner, C.]] | [[Category: Renner, C.]] | ||
[[Category: Rizkallah, P.]] | [[Category: Rizkallah, P.]] | ||
Line 50: | Line 49: | ||
[[Category: transmembrane]] | [[Category: transmembrane]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:39:43 2008'' |
Revision as of 17:39, 21 February 2008
|
STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
OverviewOverview
Analogue peptides with enhanced binding affinity to major histocompatibility class (MHC) I molecules are currently being used in cancer patients to elicit stronger T cell responses. However, it remains unclear as to how alterations of anchor residues may affect T cell receptor (TCR) recognition. We correlate functional, thermodynamic, and structural parameters of TCR-peptide-MHC binding and demonstrate the effect of anchor residue modifications of the human histocompatibility leukocyte antigens (HLA)-A2 tumor epitope NY-ESO-1(157-165)-SLLMWITQC on TCR recognition. The crystal structure of the wild-type peptide complexed with a specific TCR shows that TCR binding centers on two prominent, sequential, peptide sidechains, methionine-tryptophan. Cysteine-to-valine substitution at peptide position 9, while optimizing peptide binding to the MHC, repositions the peptide main chain and generates subtly enhanced interactions between the analogue peptide and the TCR. Binding analyses confirm tighter binding of the analogue peptide to HLA-A2 and improved soluble TCR binding. Recognition of analogue peptide stimulates faster polarization of lytic granules to the immunological synapse, reduces dependence on CD8 binding, and induces greater numbers of cross-reactive cytotoxic T lymphocyte to SLLMWITQC. These results provide important insights into heightened immunogenicity of analogue peptides and highlight the importance of incorporating structural data into the process of rational optimization of superagonist peptides for clinical trials.
DiseaseDisease
Known diseases associated with this structure: Abacavir hypersensitivity, susceptibility to OMIM:[142800], Ankylosing spondylitis, susceptibility to, 1 OMIM:[142800], Hypoproteinemia, hypercatabolic OMIM:[109700], Stevens-Johnson syndrome, susceptibility to OMIM:[142800]
About this StructureAbout this Structure
2BNR is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Structural and kinetic basis for heightened immunogenicity of T cell vaccines., Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, Choi EM, Held G, Dunbar PR, Esnouf RM, Sami M, Boulter JM, Rizkallah P, Renner C, Sewell A, van der Merwe PA, Jakobsen BK, Griffiths G, Jones EY, Cerundolo V, J Exp Med. 2005 Apr 18;201(8):1243-55. PMID:15837811
Page seeded by OCA on Thu Feb 21 16:39:43 2008
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Pages with broken file links
- Homo sapiens
- Protein complex
- Bossi, G.
- Boultier, J M.
- Cerundolo, V.
- Chen, J L.
- Choi, E M.L.
- Dunbar, P R.
- Esnouf, R M.
- Griffiths, G.
- Held, G.
- Jackobsen, B K.
- Jones, E Y.
- Lissin, N M.
- Merwe, P A.Van Der.
- Renner, C.
- Rizkallah, P.
- Sami, M.
- Sewell, A.
- Stewart-Jones, G.
- Wooldridge, L.
- Complex
- Flu
- Glycoprotein
- Immunodominance
- Mhc
- Peptide
- Polymorphism
- Receptor
- Signal
- Superagonist peptide t-cell vaccines
- T-cell
- Tcr
- Transmembrane